SeaStar Medical self-reports potential Nasdaq rule violation for share issuance

SeaStar Medical Holding Corp

Company notified Nasdaq of possible violation of Listing Rule 5635(d)(2) regarding convertible-note conversion and warrant exercise.
$9.8M convertible notes issued in four tranches with warrants equal to 25% of conversion amount per March 2023 SPA.
Aug and Dec 2023 amendments added $2.2M notes each, reset conversion price to $0.20, and issued 4,765,620 (190,624 post-R/S) and 1,055,416 (42,216 post-R/S) additional warrants.
Company requests Nasdaq determination; committed to full shareholder-approval compliance and adviser engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.